P CD70 ALLO1
Alternative Names: P-CD70-ALLO1Latest Information Update: 14 Mar 2024
At a glance
- Originator Poseida Therapeutics
- Developer Poseida Therapeutics; Roche
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Haematological malignancies
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 07 Mar 2024 Preclinical trials in Acute myeloid leukaemia in USA (Parenteral) before March 2024
- 01 Sep 2022 P CD70 ALLO1 is available for licensing as of 01 Sep 2022. https://poseida.com/science/pipeline/
- 01 Sep 2022 Preclinical trials in Haematological malignancies in USA (Parenteral) (Poseida Therapeutics pipeline, September 2022)